{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:53:49Z","timestamp":1781826829911,"version":"3.54.5"},"reference-count":53,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Patients being initiated on treatment with select immunomodulators should be screened for tuberculosis (TB) and hepatitis B virus (HBV). Previous studies found disparities in TB\/HBV screening before therapy initiation. Health-system specialty pharmacies (HSSPs) have access to electronic health records and can evaluate infection screening completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A multisite, prospective, observational cohort study was conducted at 12 HSSPs. Patients 18 years of age or older prescribed an immunomodulator between March 1 and May 31, 2023, were included. Patients prescribed medications associated with a risk of TB or HBV reactivation within the previous year or referred from a non\u2013health-system provider were excluded. Patients were followed for 6 months. Screening completion was summarized as percentages. Univariate logistic regression models were used to evaluate the association between the number of HSSP services provided and completion of safety screening, and safety screening\u2013related pharmacist interventions. Of 1,597 pharmacy referrals, 737 patients were included. Patients had rheumatological (55.5%; n = 409), dermatological (29%; n = 214), or gastroenterological conditions (15.5%; n = 114). In total, 95.1% of patients (n = 701) had any screening for TB and HBV, and 81.5% (n = 601) completed screenings within 2 years before or 60 days after referral. Screening was completed within 1 year before or 60 days after referral for 75.3% of patients (n = 555). More HSSP services were associated with increased likelihood of completed safety screening (odds ratio [OR], 1.23; P = 0.012) and pharmacist interventions (OR, 2.68; P = 0.04).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High rates of screening for TB and HBV before immunomodulator therapy initiation were observed in patients referred to HSSPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag166","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:07:35Z","timestamp":1780996055000},"source":"Crossref","is-referenced-by-count":0,"title":["High safety screening rates prior to immunomodulator initiation at health-system specialty pharmacies: A multisite, prospective, observational cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-0345","authenticated-orcid":false,"given":"Kimhouy","family":"Tong","sequence":"first","affiliation":[{"name":"Yale New Haven Health System , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C","family":"Thomas","sequence":"additional","affiliation":[{"name":"Retzky College of Pharmacy, University of Illinois Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-0691","authenticated-orcid":false,"given":"Autumn D","family":"Zuckerman","sequence":"additional","affiliation":[{"name":"Vanderbilt Specialty Pharmacy, Vanderbilt Health System , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7090","authenticated-orcid":false,"given":"Leena","family":"Choi","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gargurevich","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Godley","sequence":"additional","affiliation":[{"name":"Novant Health Specialty Pharmacy , Charlotte, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Gosser","sequence":"additional","affiliation":[{"name":"University of Washington Medicine , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanuel","family":"Kehasse","sequence":"additional","affiliation":[{"name":"Boston Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Lewis","sequence":"additional","affiliation":[{"name":"Froedtert Health Home Delivery & Specialty Pharmacy , Milwaukee, WI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Loucks","sequence":"additional","affiliation":[{"name":"University of Kansas Health System , Lenexa, KS ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"McCarthy","sequence":"additional","affiliation":[{"name":"University of Rochester Medicine , Rochester, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Pilat","sequence":"additional","affiliation":[{"name":"University of Rochester Medicine , Rochester, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Plaia","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center , , NH,","place":["Lebanon USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Rizkalla","sequence":"additional","affiliation":[{"name":"Northwell Health, Lake Success , NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"VanSice","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center , Rochester, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"9","key":"2026061819341750300_zxag166-B1","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","article-title":"Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol Int"},{"issue":"4","key":"2026061819341750300_zxag166-B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis"},{"issue":"10","key":"2026061819341750300_zxag166-B3","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1177\/2050640619883566","article-title":"Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses","volume":"7","author":"Pantavou","year":"2019","journal-title":"United European Gastroenterol J"},{"issue":"3","key":"2026061819341750300_zxag166-B4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol"},{"key":"2026061819341750300_zxag166-B5","first-page":"343","article-title":"Biological therapies for rheumatoid arthritis: an overview for the clinician","volume":"15","author":"Findeisen","year":"2021","journal-title":"Biologics"},{"issue":"1","key":"2026061819341750300_zxag166-B6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488631101160212171757","article-title":"Biologic drugs in Crohn\u2019s disease and ulcerative colitis: safety profile","volume":"11","author":"Di Sario","year":"2016","journal-title":"Curr Drug Saf"},{"issue":"2","key":"2026061819341750300_zxag166-B7","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"28","author":"Alves","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"2026061819341750300_zxag166-B8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jdv.16866","article-title":"Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014time for a paradigm change","volume":"35","author":"Nogueira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061819341750300_zxag166-B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"2026061819341750300_zxag166-B10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/EDE.0000000000001707","article-title":"Estimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States","volume":"35","author":"Ekramnia","year":"2024","journal-title":"Epidemiology"},{"issue":"3","key":"2026061819341750300_zxag166-B11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5114\/ceh.2019.87631","article-title":"Prophylaxis of hepatitis B virus (HBV) infection reactivation\u2014recommendations of the Working Group for prevention of HBV reactivation","volume":"5","author":"Paw\u0142owska","year":"2019","journal-title":"Clin Exp Hepatol"},{"key":"2026061819341750300_zxag166-B12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3899\/jrheum.140104","article-title":"Tuberculosis reactivation risk in dermatology","volume":"91","author":"Pescitelli","year":"2014","journal-title":"J Rheumatol Suppl"},{"issue":"6","key":"2026061819341750300_zxag166-B13","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0026-2016","article-title":"Biologic agents and tuberculosis","volume":"4","author":"Dobler","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"10","key":"2026061819341750300_zxag166-B14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/rheumatology\/ken242","article-title":"The British Society for Rheumatology Biologics Register: 6 years on","volume":"47","author":"Hyrich","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2026061819341750300_zxag166-B15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries","volume":"50","author":"Mariette","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2026061819341750300_zxag166-B16","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2412221","article-title":"Infection and infestation-related adverse events of biologics in psoriasis: insights from the Food and Drug Administration Adverse Event Reporting System (FAERS)","author":"Fang","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2026061819341750300_zxag166-B17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5009\/gnl19209","article-title":"Biologics for the management of inflammatory bowel disease: a review in tuberculosis-endemic countries","volume":"14","author":"Banerjee","year":"2020","journal-title":"Gut Liver"},{"key":"2026061819341750300_zxag166-B18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"issue":"1","key":"2026061819341750300_zxag166-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2026061819341750300_zxag166-B20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2026061819341750300_zxag166-B21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026061819341750300_zxag166-B22","author":"Humira (adalimumab). Package insert"},{"key":"2026061819341750300_zxag166-B23","author":"Enbrel (etanercept). Package insert"},{"key":"2026061819341750300_zxag166-B24","author":"Cimzia (certolizumab pegol). Package insert"},{"key":"2026061819341750300_zxag166-B25","author":"Simponi (golimumab)"},{"key":"2026061819341750300_zxag166-B26","author":"Xeljanz (tofacitinib). Package insert"},{"key":"2026061819341750300_zxag166-B27","author":"Olumiant (baricitinib)"},{"key":"2026061819341750300_zxag166-B28","author":"Rinvoq (upadacitinib)"},{"key":"2026061819341750300_zxag166-B29","author":"Orencia (abatacept)"},{"key":"2026061819341750300_zxag166-B30","author":"Stelara (ustekinumab)"},{"key":"2026061819341750300_zxag166-B31","author":"Tremfya (guselkumab)"},{"key":"2026061819341750300_zxag166-B32","author":"Skyrizi (risankizumab)"},{"key":"2026061819341750300_zxag166-B33","author":"Ilumya (tildrakizumab)"},{"key":"2026061819341750300_zxag166-B34","author":"Cosentyx (secukinumab)"},{"key":"2026061819341750300_zxag166-B35","author":"Taltz (ixekizumab)"},{"key":"2026061819341750300_zxag166-B36","author":"Siliq (brodalumab)"},{"key":"2026061819341750300_zxag166-B37","author":"Actemra (tocilizumab)"},{"key":"2026061819341750300_zxag166-B38","author":"Kevzara (sarilumab)"},{"key":"2026061819341750300_zxag166-B39","author":"Kineret (anakinra)"},{"key":"2026061819341750300_zxag166-B40","author":"Ilaris (canakinumab)"},{"key":"2026061819341750300_zxag166-B41","author":"Benlysta (belimumab)"},{"issue":"5","key":"2026061819341750300_zxag166-B42","first-page":"348","article-title":"Gaps in ambulatory patient safety for immunosuppressive specialty medications","volume":"45","author":"Patterson","year":"2019","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"4","key":"2026061819341750300_zxag166-B43","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1002\/hsr2.216","article-title":"Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune-mediated inflammatory diseases: a longitudinal population-based analysis using claims data","volume":"3","author":"Iba","year":"2020","journal-title":"Health Sci Rep"},{"issue":"6","key":"2026061819341750300_zxag166-B44","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.semarthrit.2020.03.003","article-title":"RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs","volume":"50","author":"Schmajuk","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2026061819341750300_zxag166-B45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3899\/jrheum.210257","article-title":"Screening for hepatitis B virus prior to initiating tocilizumab and tofacitinib in patients with rheumatic diseases: a cross-sectional study","volume":"49","author":"Mohareb","year":"2022","journal-title":"J Rheumatol"},{"issue":"4","key":"2026061819341750300_zxag166-B46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120749","article-title":"Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening","volume":"10","author":"Visram","year":"2015","journal-title":"PLoS One"},{"key":"2026061819341750300_zxag166-B47","author":"US Centers for Medicare & Medicaid Services"},{"key":"2026061819341750300_zxag166-B48","author":"US Centers for Medicare & Medicaid Services"},{"issue":"21","key":"2026061819341750300_zxag166-B49","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/ajhp\/zxac212","article-title":"Health-system specialty pharmacy role and outcomes: a review of current literature","volume":"79","author":"Zuckerman","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"13","key":"2026061819341750300_zxag166-B50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ajhp\/zxad064","article-title":"2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services","volume":"80","author":"Zuckerman","year":"2023","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"2026061819341750300_zxag166-B51","first-page":"49","article-title":"Improvement in safety monitoring of biologic response modifiers after the implementation of clinical care guidelines by a specialty","volume":"19","author":"Hanson","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"2026061819341750300_zxag166-B52","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1093\/ajhp\/zxab257","article-title":"A pharmacist-managed virtual consult service for patients with rheumatologic conditions requiring specialty or infused medications","volume":"79","author":"Sasnovskaya","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"key":"2026061819341750300_zxag166-B53","author":"Gerzenshtein"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag166\/68493096\/zxag166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag166\/68493096\/zxag166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:34:27Z","timestamp":1781825667000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag166\/8704309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag166","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"zxag166"}}